SCHEMBL30765928

SCHEMBL30765928

COc1cccc(-c2nc(C(=O)Nc3cnc(-c4ccccc4)n(CC(=O)NCc4cc5cnccc5n4S(=O)(=O)c4ccccc4)c3=O)co2)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.44
NTRK1 P04629 2/20 0.39
CASP1 P29466 1/20 0.38
KDM4E B2RXH2 1/20 0.36
TSHR P16473 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
CMA1 P23946 1/20 0.36
CTRC Q99895 1/20 0.36
MTNR1B P49286 1/20 0.36
PDE4B Q07343 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
ELANE P08246 4/20 0.35
AVPR1B P47901 3/20 0.35
NTRK3 Q16288 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765466 0.83 DGAT2 (0.47) DGAT2CASP1EGLN1CMA1CTRC
SCHEMBL30765582 0.81 KDM4C (0.42) NTRK1KDM4ETSHRMTNR1BALDH1A1
SCHEMBL30765506 0.77 NTRK1 (0.51) NTRK1CMA1CTRCNTRK3
SCHEMBL30765708 0.77 NTRK1 (0.39) NTRK1CASP1MTNR1BELANENTRK3
SCHEMBL30765816 0.76 NTRK1 (0.38) DGAT2NTRK1LMNANTRK3
SCHEMBL30765889 0.74 ELANE (0.38) DGAT2NTRK1CASP1CMA1CTRC
SCHEMBL30765443 0.73 ELANE (0.39) DGAT2NTRK1CASP1EGLN1CMA1
SCHEMBL30765590 0.72 ELANE (0.45) DGAT2CASP1ELANE
SCHEMBL30765718 0.71 NTRK1 (0.45) NTRK1CMA1CTRCMTNR1BNTRK3
SCHEMBL30766024 0.71 PDE4B (0.44) CASP1CMA1PDE4BELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed